Juan C. Osorio MD

An agonist anti-CD40 with enhanced binding to FcγRIIB showed early promise in a small cohort of patients with metastatic melanoma. Read our digest here 👉 bit.ly/4nc91nR  @juanosoriomd.bsky.social‬  @mskcancercenter.bsky.social‬

Thanks Jia!

This first study has sparked several ongoing phase-2 studies nationwide (glioblastoma, bladder and prostate cancer). Early data from these studies look promising, we look forward to reporting this! Incredibly grateful to the patients, families, philanthropic/federal support to make this possible

Preclinical work by Polina Weitzenfeld confirmed that 2142-V11 induces TLS formation across tumor models & drives antitumor responses even without lymph node trafficking, opening tons of mechanistic questions about TLS function, IT delivery and exciting avenues for subsequent combination approaches!

Another unexpected discovery was that IT 2141-V11 not only was safe but appear to trigger tertiary lymphoid structures (TLS) formation. These findings not only supports intratumoral administration as a safe approach but also the most effective way to promote optimal immune activation/interactions

Led by David Knorr, our phase trial (12 pts) showed that IT 2141-V11 was safe, and in two patients, led to sustained CR in both injected and distant, non-injected lesions, validating over a decade of preclinical findings using our humanized mouse models!

CD40 agonists have shown promise but failed due to toxicity and weak activity. We previously showed that 2141-V11, Fc-engineered for increased FcγRIIB binding, leads to superior antitumor activity and reduced toxicity when given intratumorally in preclinical models, paving the way for this trial.

Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor immunity in patients with ...

Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...

Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter @juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: https://ow.ly/O36B50W0cVS 🧪 #OncSky

Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter
@juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: ow.ly/O36B50W0cVS 🧪

#OncSky

Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org

Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: www.aacrmeetingnews.org/news/cutting... @juanosoriomd.bsky.social

Excited for tomorrow! 👇 #AACR25

Protocol for assessing antibody-dependent cellular phagocytosis by primary murine and human macrophages Macrophages play a crucial role in mediating antibody-dependent cellular phagocytosis (ADCP), a process that enhances the effectiveness of several can…

Interested in assessing antibody-dependent cellular phagocytosis by primary macrophages? Here is a practical and optimized protocol developed by dedicated and talented members of the lab, enjoy!

www.sciencedirect.com/science/arti...

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at the NIH/NCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity urldefense.com/v3/__https:/...

Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25

An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy - Nature Cancer Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.

Betty Kim & Wen Jiang and colleagues report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
@bettykimmdphd.bsky.social @wenjiang-nano.bsky.social @mdanderson.bsky.social
⬇️
www.nature.com/articles/s43...

New insights into antibody structure with implications for specificity, variable region restriction and isotype choice - Nature Reviews Immunology Immunoglobulins sample vast swathes of primary sequence and conformational space to generate and select B cell clones with exquisite selectivity and affinity for specific antigens. This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of individual antibodies.

New Perspective article from Scott McConnell & @acasadevall1.bsky.social @johnshopkinssph.bsky.social highlights the importance of constant regions in influencing the specificity and functionality of #antibodies
#immunology #immunosky

Curious if people are starting to receive NOAs more recently? Whether any signs of normalcy or whether the waiting still continues? Are these categories 1-4 now in action?

Science not silence

So needed at this moment

Same here… submitted in February 2024. Council met in September. Still waiting…

Same here, under my RFA only 3 awarded for FY25, all done from 1/16 to 1/30. Nothing after Feb 1st…

Great point, just looked! Will see if numbers of new awards start coming up in the following days 🙏🏻

I am exactly on the same boat, still waiting, despite these transient pauses and hearing that some people are getting NOAs I also have not heard a word…frustrating is a kind way to describe the feeling…

UPDATE: NIH reimposes "DEI" funding freeze despite court order The National Institutes of Health (NIH) is still blocking most ongoing scientific funding over concerns about "diversity, equity and inclusion" (DEI), according to NIH sources and internal NIH corresp...

1. UPDATE

The NIH is still blocking most ongoing scientific funding over concerns about DEI, according to NIH sources and internal NIH correspondence.

The freeze has continued even after top NIH officials acknowledged that continuing to block the funding would violate a federal court order.

U.S. early-career researchers struggling amid chaos Uncertain funding, government firings, and distressed universities hit vulnerable groups especially hard

www.science.org/content/arti...

This is concerning, I hope is not the case, that may explain the long waiting…

2141-V11: an anti-CD40 monoclonal antibody for tumor regression in patients with metastatic cancer - VJOncology Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, introduces an in-human Phase I study...

🎥 @juanosoriomd.bsky.social discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity:

➡️ https://buff.ly/3BCEtJL ⬅️

@sitcancer.bsky.social #SITC24 #Immunotherapy

Thrilled to present our for on this co-“stimulating” session organized by @sitcancer.bsky.social Join us this Thursday! Moderated by leaders in the field and presentations of exciting progress in IO for cancer. sitcancer.org/education/we...

Taking a deep breath, hoping this is a brighter sky